Alendronate in the treatment of Paget's disease of bone

Khan, S.; Vasikaran, Samuel; McCloskey, Eugène; Benéton, M. N. C.; Rogers, Susan; Coulton, Les; Orgee, Jane; Coombes, G.; Kanis, John А.

doi:10.1016/s8756-3282(96)00364-x

Cited by 42 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the recommended dose for this condition is 40 mg daily, a higher dose ± 80 mg daily ± may lead to biochemical remission in a larger proportion of patients. 72 The dose for oral risedronate in Paget's disease is 30 mg daily. 73,74 Newer and more potent drugs, such as ibandronate and zoledronate, are also being evaluated in Paget's disease.…”

Section: Paget's Disease Of Bonementioning

confidence: 99%

Bisphosphonates: an overview with special reference to alendronate

Vasikaran¹

2001

Ann Clin Biochem

106

View full text Add to dashboard Cite

Bisphosphonates, analogues of pyrophosphate, are potent inhibitors of osteoclast-mediated bone resorption. They are used in the treatment of Paget's disease of bone, hypercalcaemia and osteolytic bone disease of malignancy, primary and secondary hyperparathyroidism,and in osteoporosis. Bisphosphonate treatment causes an early reduction in bone resorption followed by a later reduction in bone formation. The early inhibition of bone resorption induces a reduction in serum calcium which leads to increased parathyroid hormone (PTH), and subsequently an increase in 1,25-dihydroxyvitamin D. The secondary hyperparathyroidism of bisphosphonate treatment also leads to urinary calcium conservation and phosphaturia, and a reduction in serum phosphate. The increase in the PTH following bisphosphonate therapy is a response to the change in serum calcium and can occur even when there is hypercalcaemia, and this can cause confusion in the interpretation of PTH results. The hypocalcaemic response to bisphosphonates is occasionally severe, especially in patients with hypoparathyroidism. The recent elucidation of bisphosphonate action at the cellular level on the mevalonate pathway has led to interest in its effects on lipoprotein metabolism, which may prove to be of clinical signi®cance. Newer and more potent bisphosphonates are currently undergoing clinical trials in malignant bone disease and osteoporosis, and will lead to further advances in the optimal management of these conditions.

show abstract

Section: Paget's Disease Of Bonementioning

confidence: 99%

Bisphosphonates: an overview with special reference to alendronate

Vasikaran¹

2001

Ann Clin Biochem

106

View full text Add to dashboard Cite

show abstract

“…Histomorphometric assessment failed to demonstrate any evidence of impaired mineralization [86,130].…”

Section: Disodium Etidronate (Ehdp)mentioning

confidence: 85%

“…Intravenous administration of 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHButBP), or 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (AHPrBP, APD), or 6-amino-1-hydroxyhexylidene-1,1-bisphosphonate (AHHexBP) induces an acute phase response (APR) which, irrespective of the underlying disease, manifests as a fall in the number of circulating lymphocytes and serum zinc concentrations, and a rise in C-reactive protein (CRP); febrile reaction occurs in 39% of patients [86].…”

Section: Bisphosphonatesmentioning

confidence: 99%

“…Aledronate is a potent amino-bisphosphonate, and one of the most popular antipagetic drugs. The drug is safe and well tolerated at a daily oral dose of 40 mg for 3-6 months [86,94,130,154], or intravenously at a dose of 10 mg daily for 5 consecutive days [114]. Aledronate has been rigorously demonstrated to heal lytic bone lesions [130] and normalize alkaline phosphatase levels by 6 months in the majority of patients.…”

Section: Disodium Etidronate (Ehdp)mentioning

confidence: 99%

“…Gastrointestinal [86] side effects occur in 25% of patients. According to the pharmaceutical company Merk & Co. Inc. (White House Station, N.J., USA), which produces the drug, adverse esophageal effects, such as esophagitis, esophageal ulcers, and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture, have been reported in patients receiving treatment with aledronite.…”

Section: Disodium Etidronate (Ehdp)mentioning

confidence: 99%

See 2 more Smart Citations